Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia cardiovascular disease. Its product candidate is gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies. The company was founded in 2008 and is headquartered in Northville, Michigan.
http://www.priceseries.com/trade/GEMP-Gemphire-Therapeutics-Inc-stock-gains-30-percent-a-Trade-Record-by-priceSeries-2018090520180925.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments